EZH2:从致癌驱动器成为克服肝细胞癌药物耐药性的治疗标
Weijing Tang1, Jianzhong Cao1, Nan Wang2
1School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
Journal of hepatocellular carcinoma
|January 7, 2026
概括
增强Zeste同源2 (EZH2) 驱动肝细胞癌 (HCC) 的耐药性. 用抑制剂或PROTAC向EZH2可能会使HCC对治疗重新敏感,从而提供新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 由于广泛的耐药性,肝细胞癌 (HCC) 存在重大治疗挑战.
- 增强Zeste同质2 (EZH2),一个关键的表观遗传调节剂,在HCC中过度表达,并导致治疗失败.
研究的目的:
- 审查EZH2通过哪些机制促进对各种HCC疗法的耐药性.
- 评估当前和新兴的EZH2抑制剂用于HCC治疗.
- 确定在HCC中针对EZH2向治疗的未来研究方向.
主要方法:
- 对研究EZH2功能在HCC耐药性中的研究的文献综述.
- 分析EZH2在调节细胞生存途径 (细胞周期,细胞亡,DNA修复) 中的作用.
- 评估EZH2对瘤微环境和免疫治疗反应的影响.
- 评估EZH2抑制剂,包括小分子和PROTACs.
主要成果:
- EZH2通过增强细胞生存途径和DNA修复来促进抵抗.
- EZH2有助于免疫抑制瘤微环境,阻碍免疫治疗.
- 在临床前模型中,各种EZH2抑制剂,包括新的模式,如PROTACs,显示出有希望的结果.
- 涉及EZH2抑制的组合策略可以克服耐药性.
结论:
- EZH2是肝细胞癌中药物耐药性的关键媒介.
- 向EZH2提供了一个有希望的策略,使HCC对化疗,向治疗和免疫治疗重新敏感.
- 进一步研究组合疗法和生物标志物开发对于推进EZH2向治疗至关重要.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


